Brought to you by 
Chiesi to sell Kamada’s inhaled anti-trypsin therapy over the next 12 years; terminated
06 Feb 2018
Executive Summary
Over the next 12 years, Chiesi Farmaceutici SPA (respiratory and critical care diseases) will have exclusive rights to market in Europe, Turkey, and the Commonwealth of Independent States Israeli biotech Kamada Ltd.’s inhaled formulation of alpha-1 antitrypsin (AAT)--in Phase II/III for alpha-1 antitrypsin deficiency (AATD), a genetic condition that can lead to lung or hepatic disorders.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Pulmonary
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Chiesi to sell Kamada’s inhaled anti-trypsin therapy over the next 12 years; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice